Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says

MT Newswires Live

2025/04/15

Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.

Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain "relatively solid and durable" in the longer term, the firm notes that the company's stock is trading "well below fundamental fair value" and offers a "buying opportunity."

The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.

Price: 94.93, Change: +4.06, Percent Change: +4.47

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2527118789"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527118789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527118789?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527118789","market":"sg","top_or_hot":-1,"title":"Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.</p><p>Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain \"relatively solid and durable\" in the longer term, the firm notes that the company's stock is trading \"well below fundamental fair value\" and offers a \"buying opportunity.\"</p><p>The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.</p><p>Price: 94.93, Change: +4.06, Percent Change: +4.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-15 00:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.</p><p>Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain \"relatively solid and durable\" in the longer term, the firm notes that the company's stock is trading \"well below fundamental fair value\" and offers a \"buying opportunity.\"</p><p>The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.</p><p>Price: 94.93, Change: +4.06, Percent Change: +4.47</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527118789","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527118789","pubTimestamp":1744648544,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences'  exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain \"relatively solid and durable\" in the longer term, the firm notes that the company's stock is trading \"well below fundamental fair value\" and offers a \"buying opportunity.\"The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.Price: 94.93, Change: +4.06, Percent Change: +4.47","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","NBIX":"神经分泌生物科学","BK4139":"生物科技","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"加拿大皇家银行表示，Neurocrine Biosciences面临的FDA和关税相关问题相对较少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain \"relatively solid and durable\" in the longer term, the firm notes that the company's stock is trading \"well below fundamental fair value\" and offers a \"buying opportunity.\"The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.Price: 94.93, Change: +4.06, Percent Change: +4.47","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}